Literature DB >> 3032210

Low plasma androgens in women with systemic lupus erythematosus.

R G Lahita, H L Bradlow, E Ginzler, S Pang, M New.   

Abstract

The high ratio of women with systemic lupus erythematosus (SLE) has remained unexplained, despite the recent description of metabolic abnormalities of estrogen and androgen metabolism. Alterations of steroid metabolism in patients with SLE could be important in the pathogenesis of this disease, since it has been reported that gonadal steroids modulate the immune system. Moreover, research with inbred lupus mice has shown that estrogens have adverse effects on the disease in both sexes, whereas androgen therapy or oophorectomy is protective in females. Recently, the finding of elevated testosterone oxidation at C-17 in females with SLE suggested that plasma androgen levels in males and females with SLE should be examined more closely. We studied the varying degrees of clinical activity, with regard to plasma levels of 4 significant androgens: testosterone, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate in a series of 5 male and 42 female SLE patients. Decreased levels of all androgens were observed in women with SLE. The lowest levels of plasma androgens were found in female patients who had active disease, as determined by laboratory and clinical assessment. These data support the fact that specific abnormalities of androgen metabolism in the female are associated with SLE, and may contribute in some way to morbidity and mortality. More importantly, these data may have implications for future therapeutic regimens based on male hormone replacement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032210     DOI: 10.1002/art.1780300301

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  39 in total

Review 1.  Can estrogens promote hypertension during systemic lupus erythematosus?

Authors:  Marcia Venegas-Pont; Michael J Ryan
Journal:  Steroids       Date:  2010-02-21       Impact factor: 2.668

2.  Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus.

Authors:  Y Tokano; A Murashima; Y Takasaki; H Hashimoto; K Okumura; S Hirose
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

Review 3.  Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  M Cutolo; A Sulli; B Villaggio; B Seriolo; S Accardo
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

4.  A potential explanation of the reported low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus.

Authors:  William H James
Journal:  Rheumatol Int       Date:  2011-03-10       Impact factor: 2.631

Review 5.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

6.  Androgen receptor (CAG)n polymorphism and androgen levels in women with systemic lupus erythematosus and healthy controls.

Authors:  Ralitsa Robeva; Dobromir Tanev; Silvia Andonova; Georgi Kirilov; Alexey Savov; Milena Stoycheva; Analia Tomova; Philip Kumanov; Rasho Rashkov; Zlatimir Kolarov
Journal:  Rheumatol Int       Date:  2013-02-07       Impact factor: 2.631

Review 7.  Pathogenesis of systemic lupus erythematosus.

Authors:  C C Mok; C S Lau
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

8.  Dehydroepiandrosterone in systemic lupus erythematosus.

Authors:  Amr H Sawalha; Susan Kovats
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

9.  Differential microRNA profile and post-transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities.

Authors:  Sudhir Kumar Chauhan; Vikas Vikram Singh; Richa Rai; Madhukar Rai; Geeta Rai
Journal:  J Clin Immunol       Date:  2014-05       Impact factor: 8.317

10.  Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.

Authors:  Mohamed A Kamal; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.